Serum tocilizumab trough concentration can be used to monitor systemic IL-6 receptor blockade in patients with rheumatoid arthritis: a prospective observational cohort study-Reference-Cited by-同舟云学术

Serum tocilizumab trough concentration can be used to monitor systemic IL-6 receptor blockade in patients with rheumatoid arthritis: a prospective observational cohort study

Published:2016-07-20 Issue:2 Volume:46 Page:87-94
ISSN:0300-9742
Container-title:Scandinavian Journal of Rheumatology
language:en
Short-container-title:Scandinavian Journal of Rheumatology

Author:

Kneepkens EL¹,van den Oever IAM¹,Plasencia CH²,Pascual-Salcedo D³,de Vries A⁴,Hart M⁵,Nurmohamed MT¹⁶,Balsa A²,Rispens T⁵,Wolbink G¹⁵

Affiliation:

1. Department of Rheumatology, Amsterdam Rheumatology and immunology Centre, location Reade, Amsterdam, The Netherlands

2. Department of Rheumatology, La Paz hospital Madrid, Spain

3. Immunology Unit, La Paz Hospital Madrid, Spain

4. Sanquin Diagnostic Services Amsterdam, The Netherlands

5. Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Centre Amsterdam, The Netherlands

6. Department of Rheumatology, Amsterdam Rheumatology and immunology Centre, VU Medical Centre, Amsterdam, The Netherlands

Publisher

Informa UK Limited

Subject

Immunology,General Medicine,Immunology and Allergy,Rheumatology

Link

https://www.tandfonline.com/doi/pdf/10.1080/03009742.2016.1183039

Reference45 articles.

1. lnterleukin-6 (IL-6) in Synovial Fluid and Serum of Patients with Rheumatic Diseases

2. Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation

3. Cytokines in the pathogenesis of rheumatoid arthritis

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A phase 3, randomized, double-blind, active-controlled clinical trial to compare BAT1806/BIIB800, a tocilizumab biosimilar, with tocilizumab reference product in participants with moderate-to-severe rheumatoid arthritis with inadequate response to methotrexate: treatment period 2 analysis (week 24 to week 48);Arthritis Research & Therapy;2024-09-07

2. Towards Personalized Medicine in Rheumatoid Arthritis;Open Access Rheumatology: Research and Reviews;2024-05

3. Tocilizumab Dose Tapering Based on a Model-Based Algorithm is Feasible in Clinical Practice: A Short Communication;Therapeutic Drug Monitoring;2024-01-24

4. Leucine-rich α2-glycoprotein as a useful biomarker for evaluating disease activity in rheumatoid arthritis;Modern Rheumatology;2023-12-23

5. Early Exposure of Kidney Transplant Recipients with Chronic Antibody-Mediated Rejection to Tocilizumab—A Preliminary Study;Journal of Clinical Medicine;2023-11-17